Vortex Energy Aktie - VRTX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

0,05

Gebot

0,045

Fragen

0,055

Volumen

4.200

0,05 Tagesbereich 0,05

0,04 52-Wochen-Bereich 0,345

Handelsende

0,05

Handelsbeginn

0,05

Letzte Trade

1000

0.05

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

122.165

Finanzvolumen

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.005	11.1111111111	0.045	0.05	0.045	10462	0.04892948	CS
4	0.005	11.1111111111	0.045	0.06	0.04	66239	0.04664521	CS
12	-0.01	-16.6666666667	0.06	0.06	0.04	122165	0.04537942	CS
26	-0.125	-71.4285714286	0.175	0.175	0.04	118491	0.07095689	CS
52	-0.28	-84.8484848485	0.33	0.345	0.04	99797	0.14370297	CS
156	-0.05	-50	0.1	2.32	0.04	191814	0.86214758	CS
260	-0.05	-50	0.1	2.32	0.04	191814	0.86214758	CS

VRTX - Frequently Asked Questions (FAQ)

What is the current Vortex Energy share price?

The current share price of Vortex Energy is $ 0,05

What is the 1 year trading range for Vortex Energy share price?

Vortex Energy has traded in the range of $ 0,04 to $ 0,345 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
MJRXGlobal Health Clinics Ltd	$ 0,02 (100,00%)	1.000
BLRBlackhawk Growth Corp	$ 0,01 (100,00%)	14k
GRUVProtium Clean Energy Corp	$ 0,035 (75,00%)	3,27M
ADPAdelphi Metals Inc	$ 0,20 (73,91%)	2,02k
GRHKGreenhawk Resources Inc	$ 0,025 (66,67%)	2,09M
WBGDWaraba Gold Limited	$ 0,005 (-50,00%)	9k
CVGRCity View Green Holdings Inc	$ 0,005 (-50,00%)	51k
CATCAT Strategic Metals Corporation	$ 0,005 (-50,00%)	52k
ASTIAquarius Surgical Technologies Inc	$ 0,01 (-50,00%)	36k
URMFirst American Uranium Inc	$ 0,015 (-40,00%)	6,84k
QIMCQuebec Innovative Materials Corp	$ 0,23 (35,29%)	6,87M
AIMLAl ML Innovations Inc	$ 0,06 (-14,29%)	3,84M
GRUVProtium Clean Energy Corp	$ 0,035 (75,00%)	3,27M
GRHKGreenhawk Resources Inc	$ 0,025 (66,67%)	2,09M
SANUSanu Gold Corp	$ 0,255 (8,51%)	1,9M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Vortex Energy Corp (VRTX) Börsenkurse

Vortex Energy Corp (VRTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

VRTX Neueste Nachrichten

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

VRTX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen